Harrow, Inc. (HROW)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1360214 · fiscal year ends in Dec
Closing price $29.98 on 29 Oct 2026; 52-week range $27.22 to $54.80.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $275.6M
- Revenue growth
- 21.1%
- Net income, last twelve months
- -$37.2M
- Earnings per share
- -$1.00
- Gross margin
- 73.3%
- Operating margin
- -1.0%
- Net margin
- -13.5%
- Free cash flow
- $5.0M
- Return on equity
- -244.9%
- Market value
- $1.1B
- Cash
- $83.9M
- Debt
- $292.4M
- Debt to equity
- 19.24
- Shares outstanding
- 37.5M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $272.3M | $30.5M | -$5.1M | -$0.14 | $43.0M | 10-K filed 2 Mar 2026 |
| FY2024 | 31 Dec 2024 | $199.6M | $8.8M | -$17.5M | -$0.49 | -$23.8M | 10-K filed 27 Mar 2025 |
| FY2023 | 31 Dec 2023 | $130.2M | $431.0K | -$24.4M | -$0.75 | $2.4M | 10-K filed 19 Mar 2024 |
| FY2022 | 31 Dec 2022 | $88.6M | $1.9M | -$14.1M | -$0.51 | -$892.0K | 10-K filed 23 Mar 2023 |
| FY2021 | 31 Dec 2021 | $72.5M | $1.6M | -$18.0M | -$0.69 | $3.3M | 10-K filed 10 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $70.7M | -$17.3M | -$0.46 |
| Q1 FY2026 | 31 Mar 2026 | $44.2M | -$27.6M | -$0.74 |
| Q4 FY2025 | 31 Dec 2025 | $89.1M | $6.6M | $0.17 |
| Q3 FY2025 | 30 Sep 2025 | $71.6M | $1.0M | $0.03 |
| Q2 FY2025 | 30 Jun 2025 | $63.7M | $5.0M | $0.13 |
| Q1 FY2025 | 31 Mar 2025 | $47.8M | -$17.8M | -$0.50 |
| Q4 FY2024 | 31 Dec 2024 | $66.8M | $6.8M | $0.19 |
| Q3 FY2024 | 30 Sep 2024 | $49.3M | -$4.2M | -$0.12 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Branded | $195.8M | 71.9% |
| ImprimisRx | $76.5M | 28.1% |
Company events
The newest 8-K filings of 269 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 5 Oct 2026 | 8-K | Deal completed, Material agreement, Investor update | 1.01, 2.01, 7.01, 9.01 |
| 4 Sep 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 10 Aug 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 6 Aug 2026 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 22 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 3 Jun 2026 | 8-K | Investor update | 7.01, 9.01 |
| 11 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 27 Mar 2026 | 8-K | Material agreement, New debt, Other events | 1.01, 2.03, 8.01, 9.01 |
| 24 Mar 2026 | 8-K | Other events | 8.01, 9.01 |
| 24 Mar 2026 | 8-K | Other events | 8.01, 9.01 |
| 10 Mar 2026 | 8-K | Investor update | 7.01, 9.01 |
| 2 Mar 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
Every filing
The newest filings with the SEC of 469 held.
| Filed | Form | Period |
|---|---|---|
| 5 Oct 2026 | 8-K | 1 Oct 2026 |
| 4 Sep 2026 | 8-K | 4 Sep 2026 |
| 10 Aug 2026 | 10-Q | 30 Jun 2026 |
| 10 Aug 2026 | 8-K | 10 Aug 2026 |
| 6 Aug 2026 | 8-K | 3 Aug 2026 |
| 22 Jun 2026 | 8-K | 18 Jun 2026 |
| 3 Jun 2026 | 8-K | 3 Jun 2026 |
| 11 May 2026 | 10-Q | 31 Mar 2026 |
| 11 May 2026 | 8-K | 11 May 2026 |
| 24 Apr 2026 | DEFA14A | – |
| 24 Apr 2026 | DEF 14A | 31 Dec 2025 |
| 27 Mar 2026 | 8-K | 24 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 14 Aug 2026 | Shojaei Amir, CHIEF SCIENTIFIC OFFICER | Sale outside a trading plan | 11,250 | $40.00 | $450.0K | 0 | 17 Aug 2026 |
| 18 May 2026 | Graves Adrienne L, Director | Purchase | 1,000 | $31.07 | $31.1K | 1,000 | 19 May 2026 |
| 18 May 2026 | Silvernail Lauren P, Director | Purchase | 1,000 | $31.00 | $31.0K | 1,000 | 19 May 2026 |
| 14 May 2026 | Baum Mark L, CHIEF EXECUTIVE OFFICER | Purchase | 10,000 | $30.20 | $302.0K | 2,996,130 | 15 May 2026 |
| 14 May 2026 | Boll Andrew R., PRESIDENT AND CFO | Purchase | 3,500 | $29.90 | $104.7K | 814,679 | 15 May 2026 |
| 4 Mar 2026 | Opaleye Management Inc., 10% owner | Sale outside a trading plan | 134,000 | $39.67 | $5.3M | 3,622,000 | 5 Mar 2026 |
| 4 Mar 2026 | Opaleye Management Inc., 10% owner | Sale outside a trading plan | 4,263 | $39.67 | $169.1K | 59,428 | 5 Mar 2026 |
| 3 Mar 2026 | Opaleye Management Inc., 10% owner | Sale outside a trading plan | 59,000 | $39.15 | $2.3M | 3,756,000 | 5 Mar 2026 |
| 3 Mar 2026 | Opaleye Management Inc., 10% owner | Sale outside a trading plan | 1,309 | $39.15 | $51.3K | 63,691 | 5 Mar 2026 |
| 27 Feb 2026 | Opaleye Management Inc., 10% owner | Sale outside a trading plan | 5,000 | $54.18 | $270.9K | 65,000 | 3 Mar 2026 |
| 6 Jan 2026 | Opaleye Management Inc., 10% owner | Sale outside a trading plan | 20,000 | $53.35 | $1.1M | 70,000 | 8 Jan 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 21 Aug 2026 | AMIR SHOJAEI, CHIEF SCIENTIFIC OFFICER | 11,250 | $450.0K | 14 Aug 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock, Inc. | 13G amended | 7.4% | 2.8M |
| 31 Jul 2026 | Opaleye Management Inc. | 13G amended | 6.44% | 2.4M |
| 11 May 2026 | Opaleye Management Inc. | 13G amended | 7.61% | 2.8M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 11 Mar 2026 | Daniel Kaufman | 13G | 5.04% | 1.9M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 7.5M | -3.71% | 11.23 |
| 30 Sep 2026 | 7.8M | +3.66% | 12.38 |
| 15 Sep 2026 | 7.5M | +10.46% | 15.68 |
| 31 Aug 2026 | 6.8M | +6.62% | 13.69 |
| 14 Aug 2026 | 6.4M | -6.26% | 10.31 |
| 31 Jul 2026 | 6.8M | -0.9% | 11.77 |
| 15 Jul 2026 | 6.8M | -4.25% | 12.62 |
| 30 Jun 2026 | 7.1M | -2.17% | 7.75 |
Funds that hold it
From each fund's latest Form 13F.
257 funds held it at 30 Jun 2026: 110 added and 64 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 2,740,117 | $116.4M | +187,358 |
| Opaleye Management Inc. | 2,400,000 | $101.9M | -432,230 |
| Private Capital Management, LLC | 1,598,770 | $67.9M | +36,770 |
| Vanguard Capital Management LLC | 1,417,212 | $60.2M | +14,156 |
| Deep Track Capital, LP | 969,000 | $41.2M | +969,000 |
| State Street Corp. | 939,888 | $39.9M | +84,841 |
| Geode Capital Management, LLC | 905,560 | $38.5M | +53,526 |
| Bamco Inc. | 809,350 | $34.4M | +809,350 |
| Dimensional Fund Advisors LP | 667,036 | $28.3M | +87,516 |
| Jupiter Topco LLC | 579,127 | $24.6M | – |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B